Phenix

Leidos to Develop Autonomous Uncrewed Aerial Resupply System for U.S. Marine Corps

Retrieved on: 
Tuesday, April 18, 2023
LDOS, Marine Corps Systems Command, UAS, Phenix, Marines, Science, Radius, NYSE, Shipbuilding, Leidos

RESTON, Va., April 18, 2023 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to develop an uncrewed aircraft system (UAS) that can autonomously resupply forward-deployed ground forces.

Key Points: 
  • RESTON, Va., April 18, 2023 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to develop an uncrewed aircraft system (UAS) that can autonomously resupply forward-deployed ground forces.
  • The firm-fixed-price, multiple-award contract has a period of performance of 18 months to build a single prototype for the Marine Corps.
  • "Leidos leads the industry in taking cutting-edge innovations and making them mission-ready today," said Tim Freeman, Leidos senior vice president and Airborne Solutions operations manager.
  • Under the contract, Leidos will develop, deliver and demonstrate an autonomous medium unmanned logistics system – air (MULS-A) prototype.

STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. and Encourages Long-Term FIXX Stockholders to Contact the Firm

Retrieved on: 
Monday, March 6, 2023
Defendant, Phenix, Acquisition, Clinical trial, Phenylketonuria, Complaint, Phenylalanine, FDA, Brain damage, Pharmaceutical industry

PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term stockholders.

Key Points: 
  • PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term stockholders.
  • Current Homology stockholders who purchased or acquired shares of the Company’s stock prior to March 12, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Onboard Systems Selected for Ultra 2XL Heavy-Lift UAS Program by Phenix Solutions

Retrieved on: 
Monday, March 6, 2023
Aircraft, Marketing, Pedigree, Certification, HAI, Ultra, Partnership, UAS, Forestry, Dredging, Phenix

VANCOUVER, Wash., March 6, 2023 /PRNewswire/ -- Onboard Systems today announced that it has been selected by Phenix Solutions Inc. of McMinneville, Oregon, as a partner to develop a multi-use cargo hook system for the Ultra 2XL Heavy-Lift Cargo Aircraft Unmanned Aircraft System (UAS).

Key Points: 
  • VANCOUVER, Wash., March 6, 2023 /PRNewswire/ -- Onboard Systems today announced that it has been selected by Phenix Solutions Inc. of McMinneville, Oregon, as a partner to develop a multi-use cargo hook system for the Ultra 2XL Heavy-Lift Cargo Aircraft Unmanned Aircraft System (UAS).
  • The Phenix-Onboard partnership will leverage Onboard Systems' 40-plus years as the leading provider of external load equipment for the helicopter industry with Phenix Solutions' state-of-the-art drone platform program.
  • According to Phenix Solutions President & CEO, Brian Reese, "Working with Onboard is a considerable step forward for Phenix Solutions and the Ultra 2XL program as we are moving from the stages of building our UAS aircraft to focusing on the mission equipment and accessory products.
  • An Ultra 2XL with an Onboard Systems cargo hook and other Onboard products will be on display at the Phenix booth (B3438) to enable customers to envision the Ultra 2XL's potential multi-mission capabilities.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm

Retrieved on: 
Monday, December 12, 2022
Acquisition, Phenix, Defendant, Clinical trial, Phenylalanine, FDA, Phenylketonuria, Complaint, Brain damage, Pharmaceutical industry

PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term investors.
  • Current Homology stockholders who purchased or acquired shares of the Company’s stock prior to June 1, 2019 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Thursday, November 10, 2022
Pfizer, IND, Phenix, Research, Securities Exchange Act of 1934, Company, Program, Security (finance), Personal Data Privacy and Security Act of 2009, Scientific Reports, Director, Genetics, Chairperson, Spoke, Society, Cell, Board, Securities Act of 1933, Hunter syndrome, PNH, U.S. Securities and Exchange Commission, AAV, Novartis, Patient, CEO, Private law, COVID-19, Private Securities Litigation Reform Act, Nasdaq, Mesa, Paroxysmal nocturnal hemoglobinuria, Phenylketonuria, Antibody, Gene editing, Clinical trial, MPS II, Central nervous system, MPS, GLOBE, Investment, Intention, Failure, Safety, Disease, Solution, MLD, JumpStart, Therapy, PKU, Pharmaceutical industry, Cryptocurrency, Vaccine, Nature

BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.

Key Points: 
  • BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.
  • Collaboration revenues for the quarter ended September 30, 2022 were $0.8 million, compared to $1.7 million for the quarter ended September 30, 2021.
  • Research and development expenses for the quarter ended September 30, 2022 were $25.9 million, compared to $24.0 million for the quarter ended September 30, 2021.
  • General and administrative expenses for the quarter ended September 30, 2022 were $7.8 million, compared to $8.4 million for the quarter ended September 30, 2021.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm

Retrieved on: 
Friday, September 16, 2022
Time, FDA, Acquisition, Clinical trial, Complaint, Phenylketonuria, Phenix, Defendant, NASDAQ, Phenylalanine, GLOBE, Brain damage, Security (finance), Pharmaceutical industry

PHILADELPHIA, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term investors.

Key Points: 
  • PHILADELPHIA, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term investors.
  • HMI-102 is a gene therapeutic designed to treat phenylketonuria (PKU), a genetic condition that can lead to excessive phenylalanine levels and brain damage.
  • Current Homology stockholders who purchased or acquired shares of the Companys stock prior to June 1, 2019 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation, and has helped recover in excess of $100 million on behalf of victimized investors.

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, GLOBE, Failure, SEC, Investment, Phenix, Security (finance), Research, Pfizer, MLD, Steroid, Patient, Private law, Phenylketonuria, Hunter syndrome, Immunosuppression, Food, Disease, Liver, Private Securities Litigation Reform Act, Investigational New Drug, Safety, Novartis, Paroxysmal nocturnal hemoglobinuria, Nasdaq, Conference, PNH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PKU, Confirmation, Gene editing, COVID-19, Program, Health Canada, Solution, National, FDA, Antibody, Population, Workforce, Company, C5, Therapy, Central nervous system, Tyrosine, JumpStart, PAH, Pharmaceutical industry, Vaccine, IND

Homology has a strong cash position that is now expected to take us into the fourth quarter of 2024.

Key Points: 
  • Homology has a strong cash position that is now expected to take us into the fourth quarter of 2024.
  • This program represents a third part of Homologys platform, and we believe it provides the opportunity to address potentially larger market indications.
  • Collaboration revenues for the quarter ended June 30, 2022 were $0.8 million, compared to $2.2 million for the quarter ended June 30, 2021.
  • Research and development expenses for the quarter ended June 30, 2022 were $21.1 million, compared to $23.7 million for the quarter ended June 30, 2021.

PIXABILITY ADDS THREE KEY EXECS INCLUDING FORMER PRESIDENT OF OPENSLATE

Retrieved on: 
Wednesday, July 27, 2022
Red Bull GmbH, Nokia, Sale, The Interpublic Group of Companies, Hulu, Spitzer, The Wall Street Journal, KIND, OpenSL ES, Publicis, CEO, VP, Agency, Puma, CTV, Software, Solution, Connected, Dentsu, Advertising, Smart TV, CBS, MarketWatch, WPP, One by AOL, DSP, Integral Ad Science, Box, Omnicom Group, EVP, Technology, AOL, SVP, Software as a service, Enpocket, Discovery, Inc., Phenix, Amazon Fire tablet, Growth, Founder, GroupMe, Video game, Public relations, YouTube, Swatch, Roku, Bose

BOSTON, July 27, 2022 /PRNewswire/ -- Pixability (www.pixability.com), the only provider of brand suitability, performance, and insights software for advertising on YouTube and other leading Connected TV platforms, today announced that it will be adding three key executives to its leadership team. Brian Quinn, the former president of OpenSlate (acquired by DoubleVerify) will join as Chief Growth Officer to accelerate further growth as Pixability expands deeper into Brand Suitability and CTV markets. Brent Spitzer, an ad tech industry veteran, will join as EVP of Sales to lead Pixability's growing sales team. Jon Phenix, a veteran of CTV companies Roku and dataXu, will join as SVP, Independent Agencies, and will drive a key component of Pixability's CTV expansion. The additions come after a record first half of 2022 which follows two straight years of record revenue growth and profitability. This growth has been driven by innovation in YouTube brand suitability and performance technology as well as new product solutions that enable market-leading reach across Connected TV platforms.

Key Points: 
  • Brian Quinn, the former president of OpenSlate (acquired by DoubleVerify) will join as Chief Growth Officer to accelerate further growth as Pixability expands deeper into Brand Suitability and CTV markets.
  • Brian Quinn comes to Pixability from OpenSlate where he was President and led global sales and business development until the company's sale to DoubleVerify in November 2021.
  • Brent comes to Pixability with over 20 years of sales leadership experience at digital media, ad tech and SaaS companies.
  • Prior to joining Pixability, Brent served as head of sales at a number of ad tech and digital startups including Jellysmack, SayitNow.ai and Fuisz Video.

BIMI Enters into Definitive Agreement to Acquire Phenix Bio Inc.

Retrieved on: 
Thursday, July 7, 2022
Acquisition, Patient, GLOBE, COVID-19, Growth, Company, Annual report, U.S. Securities and Exchange Commission, SPA, Male, BIMI, Risk, NASDAQ, News, 3D printing, Health insurance, Phenix

New York, July 07, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced that on July 5, 2022, the Company entered into a definitive stock purchase agreement (the "SPA") to acquire Phenix Bio Inc. (“Phenix”), a California based corporation that will distribute healthcare products. This acquisition is a critical initiative to advance the Company's business strategy to expand its business scale and fuel its growth.

Key Points: 
  • New York, July 07, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (BIMI or the Company), a healthcare products and services provider, today announced that on July 5, 2022, the Company entered into a definitive stock purchase agreement (the "SPA") to acquire Phenix Bio Inc. (Phenix), a California based corporation that will distribute healthcare products.
  • This acquisition is a critical initiative to advance the Company's business strategy to expand its business scale and fuel its growth.
  • The audit committee and the board of directors of the Company unanimously approved the Companys entry into the SPA.
  • Mr.Tiewei Song, Chief Executive Officer of BIMI International Medical Inc., commented, We are excited to acquire Phenix and thrilled about the opportunity ahead of us as Phenix is in the process of securing exclusive distribution rights for nine healthcare products.

Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

Retrieved on: 
Wednesday, June 29, 2022
PKU, Patient, Genome, PNH, GLOBE, Phenix, Hunter syndrome, Company, Disease, MLD, Phenylketonuria, Paroxysmal nocturnal hemoglobinuria, Therapy, Gene editing, Hepatocyte, PAH, Antibody, Nasdaq, Gene, Conference, Model, Pharmaceutical industry, Communications satellite, Vaccine, Research

2022 NPKUA Conference on July 7-10, 2022 in Vancouver, WA

Key Points: 
  • 2022 NPKUA Conference on July 7-10, 2022 in Vancouver, WA
    Gene Editing and Gene Therapy for PKU, during the panel session, Whats New in PKU?
  • Homology Medicines is conducting two clinical trials for adults with PKU.
  • The pheEDIT trial is evaluating HMI-103, a one-time gene editing product candidate designed to integrate the PAH gene into the genome for a permanent correction.
  • The Companys clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome.